Key message:
3-dose COVID-19-vaccine has excellent safety profile in adolescents with
rheumatic diseases; minimal risk of exacerbation. Adequate long-term
immunogenicity in healthy controls and most rheumatic adolescents; the
third dose restored titres. Breakthrough COVID-19 infection rates and
time from last vaccination to infection were similar between groups.
BNT162b2 mRNA COVID-19 booster vaccine is recommended for adolescents
with rheumatic diseases